Department of Oncology, Santa Maria della Misericordia University Hospital, ASUFC, Udine, Italy.
Collegio Italiano dei Primari Oncologi Medici Ospedalieri (CIPOMO), Genova, Italy.
Oncologist. 2023 Jun 2;28(6):e324-e330. doi: 10.1093/oncolo/oyad020.
Two main aspects lead the implementation of precision oncology into clinical practice: the adoption of extended genome sequencing technologies and the institution of the Molecular Tumor Boards (MTBs). CIPOMO (Italian Association of Heads of Oncology Department) promoted a national survey across top health care professionals to gain an understanding of the current state of precision oncology in Italy.
Nineteen questions were sent via the SurveyMonkey platform to 169 heads of oncology departments. Their answers were collected in February 2022.
Overall, 129 directors participated; 113 sets of answers were analyzed. Nineteen regions out of 21 participated as a representative sample of the Italian health care system. The use of next-generation sequencing (NGS) is unevenly distributed; informed consent and clinical reports are managed differently, as the integration of medical, biologic, and informatics domains in a patient-centered workflow is inconsistent. A heterogeneous MTB environment emerged. A total of 33.6% of the responding professionals did not have access to MTBs while 76% of those who have did not refer cases.
NGS technologies and MTBs are not homogeneously implemented in Italy. This fact potentially jeopardizes equal access chances to innovative therapies for patients. This survey was carried out as part of an organizational research project, pursuing a bottom-up approach to identify the needs and possible solutions to optimize the process. These results could be a starting point for clinicians, scientific societies, and health care institutions to outline the best practices and offer shared recommendations for precision oncology implementation in current clinical practice.
精准肿瘤学在临床实践中的实施主要有两个方面：扩展基因组测序技术的采用和分子肿瘤委员会（MTB）的建立。CIPOMO（意大利肿瘤科主任协会）在意大利全国范围内对医疗保健专业人员进行了一项调查，以了解当前意大利精准肿瘤学的现状。
通过 SurveyMonkey 平台向 169 名肿瘤科主任发送了 19 个问题。他们的答案于 2022 年 2 月收集。
共有 129 位主任参与；分析了 113 套答案。21 个地区中的 19 个作为意大利医疗保健系统的代表性样本参与其中。下一代测序（NGS）的使用分布不均；知情同意和临床报告的管理方式不同，因为在以患者为中心的工作流程中整合医学、生物学和信息学领域的工作方式不一致。出现了一个异质的 MTB 环境。总共 33.6%的参与专业人员无法获得 MTB，而那些有 MTB 的人中有 76%没有转诊病例。
NGS 技术和 MTB 在意大利的实施并不均匀。这一事实可能会危及患者获得创新疗法的平等机会。这项调查是作为组织研究项目的一部分进行的，旨在采用自下而上的方法来确定需求和可能的解决方案，以优化流程。这些结果可以为临床医生、科学协会和医疗机构提供一个起点，为当前临床实践中的精准肿瘤学实施制定最佳实践并提供共享建议。
